Neural Lipids in Parkinson's Disease

  • M. Barichella
  • G. Pezzoli
  • A. Mauri
  • C. Savardi
Reference work entry


A huge scientific effort is still ongoing in order to address the main etiologic and pathologic mechanisms responsible for the onset and the progression of Parkinson's Disease, one of the most common chronic progressive neurological disorders. The key role of oxidative damage in PD has been widely studied. Exposition to different toxic agents can promote oxidative damages, for instance, via inhibition of mitochondrial functions. This can lead to the formation of dangerous reactive radical compounds and of their relative oxidation products which have been frequently discovered to be present in elevated concentration in the Substantia Nigra pars compacta neurons of PD affected patients. In particular, being cellular membranes a preferential site for lipid oxidation, of increasing importance are also the studies investigating the contribution of membrane lipids composition to the aggregation of the α-Synuclein protein in filamentous amyloid-like fibrils, giving origin to insoluble intracellular inclusions with the capacity to cause neuronal damage. More recently, the role of the Cannabinoid-based compounds on the endocannabinoid receptors is under investigation due to the suggestions of a close interaction of the dopaminergic transmission with the endocannabinoid system which could ultimately behave as a compensatory mechanism in case the functionality of previous one is compromised. These compounds could thus be considered as a potential therapy to alleviate motor symptoms and L-dopa associated dyskinesias in PD affected patients.


Substantia Nigra Parkinson Study Group Parkinsonian Brain Calcium Binding Protein Calbindin Binding Protein Calbindin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:




adenosine triphosphate


type 1 cannabinoid receptors


type 2 cannabinoid receptors


central nervous system


electron transport chain




glutathione disulfide


hydrogen peroxide




Lewy bodies


Lewy neurites


enzyme monoamine oxidase






nitric oxide


nitric oxide synthase


hydroxyl free radical


Parkinson's Disease


reactive nitrogen species


reactive oxygen species


human α-Synuclein gene


substantia nigra pars compacta


superoxide dismutase


  1. Adams JD Jr, Odunze IN. 1991. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Biochem Pharmacol 41: 1099–1105.PubMedCrossRefGoogle Scholar
  2. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, et al. 1997. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidetal Lewy Body disease. J Neurochem 69: 1326–1329.PubMedCrossRefGoogle Scholar
  3. Bolanos JP, Peuchen S, Heales SJR, Land JM, Clark JB. 1994. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astroytes. J Neurochem 63: 910–916.PubMedCrossRefGoogle Scholar
  4. Braak E, Sandmann-Keil D, Rub U, Gai WP, de Vos RA, et al. 2001. Alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol 101: 195–201.PubMedGoogle Scholar
  5. Bussel R Jr, Eliezer D. 2004. Effects of Parkinson's disease-linked mutations on the structure of Lipid-associated α-Sinuclein. Biochemistry 43: 4810–4818.CrossRefGoogle Scholar
  6. Camandola S, Poli G, Mattson MP. 2000. The lipid peroxidation product 4-hydroxy-2,3-nonenal increases AP-1-binding activity through caspase activation in neurons. J Neurochem 74: 159–168.PubMedCrossRefGoogle Scholar
  7. Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AHV. 1994. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: Implications for neurodegenerative diseases. FEBS Lett 345: 50–54.PubMedCrossRefGoogle Scholar
  8. Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, et al. 2002. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein α-Sinuclein. J Biol Chem 277: 6344–6352.PubMedCrossRefGoogle Scholar
  9. Corey S. 2005. Recent developments in the therapeutic potential of cannabinoids. P R Health Sci J 24: 19–26.PubMedGoogle Scholar
  10. Damier P, Hirsch EC, Agid Y, Graybiel AM. 1999. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122: 1437–1448.PubMedCrossRefGoogle Scholar
  11. Dawson TM, Dawson VL. 2003. Molecular pathways of neurodegeneration in Prkinson's disease. Science 302: 819–822.PubMedCrossRefGoogle Scholar
  12. de Rijk MC, Breteler MM, den Breeijen JH, Launer LJ, Grobbee DE, et al. 1997. Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch Neurol 54: 762–765PubMedGoogle Scholar
  13. El-Agnaf OM, Jakes R, Curran MD, Wallace A. 1998. Effects of the mutations Ala30 to Pro and Ala53 to Thr on physical and morphological properties of alpha-sinuclein protein in Parkinson's disease. FEBS Lett 440: 67–70.PubMedCrossRefGoogle Scholar
  14. Fahn S, Przedborski S. 2005. Merritt's Neurology, 11th edition edit by Lewis P. Rowland 2005 by Lippincott Williams & Wilkins ( Philadelphia, USA; pp. 828–846.Google Scholar
  15. Fahn S, The Parkinson Study Group. 2005. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 252 (Suppl 4): IV37–IV42.PubMedCrossRefGoogle Scholar
  16. Farooqui AA, Horrocks LA. 1998. Lipids peroxides in the free radical pathophysiology of brain diseases. Cell Mol Neurobiol 18: 599–608.PubMedCrossRefGoogle Scholar
  17. Fernandez-Ruiz J, Gonzales S. 2005. Cannabinoid control of motor function at the basal ganglia. Handb Exp Pharmacol 168: 479–507.PubMedCrossRefGoogle Scholar
  18. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. 2003. Effects of levodopa on endocannabinoid levels in rat basal ganglia: Implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 18: 1607–1614.PubMedCrossRefGoogle Scholar
  19. Floor E, Wetzel MG. 1998. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with improved dinitrophenylhydrazine assay. J Neurochem 70: 268–275.PubMedCrossRefGoogle Scholar
  20. Forno LS. 1996. J Neuropathol Exp Neurol. 55: 259–272.PubMedCrossRefGoogle Scholar
  21. Giasson BI, Galvin JE, Lee VM, Trojanowski JQ. 2000. Clark CM, Trojanowski JQ, editors. Neurodegenerative Dementias. New York: McGraw Hill; pp. 219–228.Google Scholar
  22. Giasson BL, Uryu K, Trojanowski JQ, Lee VM. 1999. Mutant and wild-type human alpha-sinucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274: 7619–7622.PubMedCrossRefGoogle Scholar
  23. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, et al. 2002. Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission. J Neurosci 22: 6900–6907.PubMedGoogle Scholar
  24. Giuffrida A, Leweke FM, Gerrh CW, Schreiber D, Koethe D, et al. 2004. Cerebrospinal anandamide levels in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108–2114.PubMedCrossRefGoogle Scholar
  25. Golbe LI, Langston JW. 1993. The etiology of Parkinson's disease: New directions for research. Parkinson's disease and movement disorders. Jankovic J, Tolosa E, editors. Baltimore: Williams and Wilkins; pp. 93–102.Google Scholar
  26. Halliwell B, Gutteridge JMC. 1999. Free Radicals in Biology and Medicine. 3rd edition. Oxford: University Press.Google Scholar
  27. Halliwell B. 2001. Role of free radicals in the neurodegenerative diseases. Therapeutic implicants for antioxidant treatment. Drugs Aging 18: 685–716.PubMedCrossRefGoogle Scholar
  28. Hefti F, Melamed E, Bhawan J, Wurtman R. 1981. Long term administration of l-dopa does not damage dopaminergic neurons in the mouse. Neurology 31: 1194–1195.Google Scholar
  29. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, et al. 1996. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72: 355–363.PubMedCrossRefGoogle Scholar
  30. Jellinger KA. 2002. Recent developments in pathology of Parkinson disease. J Neural Transm 62: 347–376.Google Scholar
  31. Jenco JM, Rawiingson A, Daniels B, Morris AJ. 1998. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37: 4901–4909.PubMedCrossRefGoogle Scholar
  32. Jenner P, Marsden CD. 1981. MPTP-induced parkinsonism: A model of Parkinson's disease and its relevance to the disease process. Movement Disorders, Neurology 2. Marsden CD, Fahn S, editors. London: Butterworth Scientific; pp. 55–75.Google Scholar
  33. Jenner P, Olanow CW. 1996. Oxidative stress and pathogenesis of Parkinson's disease. Neurology 47: S161–S170.PubMedGoogle Scholar
  34. Jenner P. 2003. Oxidative stress in Parkinson's disease. Ann Neurol 53: S26–S38.PubMedCrossRefGoogle Scholar
  35. Jo E, Puller N, Rand RP, George-Hyslop P, Fraser PE. 2002. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-sinuclein. J Mol Biol 315: 799–807.PubMedCrossRefGoogle Scholar
  36. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K. 2000. d-β-Hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease.Google Scholar
  37. Kreutzberg GW. 1996. Microglia: A sensor of pathological events in CNS. Trends Neurosci. 19: 312–318.PubMedCrossRefGoogle Scholar
  38. Krüger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. 1998. Ala30Pro mutation in the gene encoding alpha-sinuclein in Parkinson's disease. Nat Genet 18: 106–108.PubMedCrossRefGoogle Scholar
  39. Lang AE, Lozano AM. 1998. Parkinson's disease. First of two parts. N Engl J Med 339: 1044–1053.PubMedCrossRefGoogle Scholar
  40. Lashuel HA, Hartley D, Petre BM, Waltz T, Lansbury PT Jr. 2002. Nature 418: 291.PubMedCrossRefGoogle Scholar
  41. Lee FJ, Liu F, Pristupa ZB, Niznik HB. 2001. Direct binding and functional coupling of alpha-sinuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15: 916–926.PubMedCrossRefGoogle Scholar
  42. Liu W, Kato M, Akhand AA, Hayakawa A, Suzuki H, et al. 2000. 4-Hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. J Cell Sci 113: 635–641.PubMedGoogle Scholar
  43. Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, et al. 2002. Chronic high dose l-dopa alone or in combination with COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 109(1): 53–67.PubMedCrossRefGoogle Scholar
  44. Matsubara K, Kobayashi S, Kobayashi Y, Yamashita K, Koide H, et al. 1995. β-Carbolinium cations, endogenous MPP + analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 45: 2240–2245.PubMedGoogle Scholar
  45. Mufson EJ, Brandabur MM. 1994. Sparing of NADPH-diaphorase striatal neurons in Parkinson's and Alzheimer's diseases. Neuroreport 5: 705–708.PubMedCrossRefGoogle Scholar
  46. Olanow CW, Jenner P, Tatton WG. 1998. Neurodegeneration and Parkinson's disease. Parkinson's Disease and Movement Disorders. Jankovic J, Tolosa E, editors. Baltimore: Williams & Wilkins; pp. 67–103.Google Scholar
  47. Parkinson Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176–183.CrossRefGoogle Scholar
  48. Perrin RJ, Woods WS, Clayton DF, George JM. 2000. Interaction of human alpha-sinuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenis. J Biol Chem 275: 34393–34398.PubMedCrossRefGoogle Scholar
  49. Pezzoli G, Antonini A, Barbieri S, Canesi M, Perbellini L, et al. 1995. n-Hexane-induced parkinsonism: Pathogenetic hypotheses. Mov Disord 3: 279–282.CrossRefGoogle Scholar
  50. Pezzoli G, Canesi M, Antonini A, Righini A, Perbellini L, et al. 2000. Hydrocarbon exposure and Parkinson's disease. Neurology 55: 667–673.PubMedGoogle Scholar
  51. Picklo MJ, Amarnath V, McIntyre JO, Graham DG, Montine TJ, 1999. 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 72: 1617–1624.PubMedCrossRefGoogle Scholar
  52. Piomelli D. 2003. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 4: 873–884.PubMedCrossRefGoogle Scholar
  53. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, et al. 2005. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 57: 777–779.PubMedCrossRefGoogle Scholar
  54. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. 1997. Mutation in alpha-sinuclein gene identified in families with Parkison's disease. Science 276: 2045–2047.PubMedCrossRefGoogle Scholar
  55. Radi R, Beckman JS, Bush KM, Freeman BA. 1991. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288: 481–487.PubMedCrossRefGoogle Scholar
  56. Reif DW, Simmons RD. 1990. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 283: 537–541.PubMedCrossRefGoogle Scholar
  57. Saggu H, Cooksey J, Dexter DH, Wells FR, Lees A, et al. 1989. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692–697.PubMedCrossRefGoogle Scholar
  58. Saito H, Lund-Katz S, Phillips MC. 2004. Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog Lipid Res 43: 350–380.PubMedCrossRefGoogle Scholar
  59. Scherzer CR, Feany MB. 2004. Yeast genetics targets lipids in Parkinson's disease. Trends genet 20: 273–277.PubMedCrossRefGoogle Scholar
  60. Scotcher KP, Irwin I, De Lanney LE, Langston JW, Di Monte D. 1990. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion in ATP levels of mouse brain synaptosomes. J Neurochem 54: 1295–1301.PubMedCrossRefGoogle Scholar
  61. Segovia G, Mora F, Crossman AR, Brotchie JM. 2003. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesias induced by high-dose levodopa in reserpine-treated rat model of Parkinson's disease. Mov Disord 18: 138–149.PubMedCrossRefGoogle Scholar
  62. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, et al. 2003. The formation of highly soluble oligomers of α-sinuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37: 583–595.PubMedCrossRefGoogle Scholar
  63. Wersinger C, Sidhu A. 2003. Attenuation of dopamine transporter activity by alpha-sinuclein. Neurosci Lett 340: 189–192.PubMedCrossRefGoogle Scholar
  64. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, et al. 1996. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc Natl Acad Sci USA 93: 2696–2701.PubMedCrossRefGoogle Scholar
  65. Yoshida M, Niwa T, Nagatsu T. 1990. Parkinson in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes. Neurosci Lett 119: 109–113.PubMedCrossRefGoogle Scholar
  66. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, et al. 1999. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423–1429.PubMedCrossRefGoogle Scholar
  67. Zhu M, Li J, Fink AL. 2003. The association of α-sinuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem 278 (41): 40186–40197.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • M. Barichella
  • G. Pezzoli
  • A. Mauri
  • C. Savardi

There are no affiliations available

Personalised recommendations